초록

1세부: IGF-1 약물 함유히알루론산(약물 95%이상함유) 및 덱사메타손 함유 PLGA 미립구(약물 60%이상함유) 제조와 전달체내의 약물의 서방화을 확인 평가 중이며, 생체 적용 가능한 주사제형 제조 진행 중
2세부:난청 동물모델 확립 (이독성 난청, 소음성 난청), 이중약물 복합 주사제형 전달체의 난청 치료 효과 규명, 이중약물 복합 주사제형 전달체의 약물 전달 기전과 영상화 방법 연구

(출처 : 보고서 요약서 3p)

Abstract ▼

Ⅳ. Results
○ Preparation of drug-loaded carrier
- IGF-1-loaded HA (Drug loading >95%) and dexamethasone-loaded PLGA sphere (Drug loading >60%)
- Drug releasing (maintain for 16 days)
○ Preparation of molecular imaging agent-loaded carrier (Joint research with Harvard)
- In vivo tra

Ⅳ. Results
○ Preparation of drug-loaded carrier
- IGF-1-loaded HA (Drug loading >95%) and dexamethasone-loaded PLGA sphere (Drug loading >60%)
- Drug releasing (maintain for 16 days)
○ Preparation of molecular imaging agent-loaded carrier (Joint research with Harvard)
- In vivo tracking of drug
○ Preparation of dual drug injectable delivery
- Preparation of IGF-1-loaded hyaluronic acid hydrogel /dexamethasone-loaded PLGA sphere
- In vivo drug depot formation no more than few second
○ Establishment of noise induced hearing loss animal model
- White noise 120dB SPL noise was deliverd to reuslt in consistent 50-60dB SPL hearing loss.
○ Verification of the safety by tympanic endoscopy and mico CT
- Some inflammation was found in the tympanic membrane for certain vehicles. But the inflammation subsided in all animals regardless of the vehicle. Each vehicle showed different incidence and degree of inflammation.
○ Verification of the efficacy by cochlear hair cell count
- Number of hair cells were counted within 200μm of each cochlear turn with a confocal microscopic image. This research is on going.
○ Verification of the safety by histologic section of the middle ear bulla
- After 8 days of injection, the middle ear bulla was harvested and prepared for histologic evaluation. This research is on going.
○ Establishment of ototoxic hearing loss animal model
- When hearing loss was caused by 3NP intratympanic injection, 60-70 dB SPL hearing loss was resulted. When hearing loss was caused by gentamicin and furosimide, 45-60 dB SPL hearing loss was resulted. We were able to control the amount of hearing loss with different medications and administration methods.
○ Verification of the efficacy by hearing level
- When noise indueced hearing loss was treated with several different vehicles, HA+dexa group showed a better treatment outcome compared to PCL+dexa, saline+dexa, and complete control group.
○ imaging the inner ear with 9.4 T MRI
- 9.4 Tesla micro MRI was scanned with two different gadolinium based contrast agents. We found that GdDO3A-butrol was superior to Gd-DOTA in visualizing the inner ear. And this difference was 67% better for GdDO3A-butrol. 2.5 hr after GdDO3A-butrol injection seems to be the best method of imaging for Meniere’s disease.

(출처 : SUMMARY 7p)

목차 Contents

• 표지 ... 1
• 제 출 문 ... 2
• 보고서 요약서 ... 3
• 요 약 문 ... 4
• Summary ... 7
• Contents ... 9
• 목차 ... 10
• 제1장 연구개발과제의 개요 ... 11
• 1. 연구개발의 목적 ... 11
• 2. 연구개발의 필요성 ... 16
• 제2장 국내외 기술개발 현황 ... 19
• 1. 국내외 예방/치료 약물 기술 현황 ... 19
• 2. 국내외 연구현황 ... 20
• 3. 연구개발대상 기술의 국내 수준 ... 21
• 제3장 연구개발수행 내용 및 결과 ... 22
• 1. 연구수행 내용 ... 22
• 2. 연구수행 결과 ... 26
• 제4장 목표달성도 및 관련분야에의 기여도 ... 42
• 1. 연구개발의 최종목표 ... 42
• 제5장 연구개발결과의 활용계획 ... 43
• 제6장 연구개발과정에서 수집한 해외과학기술정보 ... 44
• 제7장 참고문헌 ... 45
• 끝페이지 ... 47